VM Index subscribers see full details of all IT Venture Capital deals from the past week plus profiles and analysis of thousands of investors and venture-backed companies.

VM Index subscribers see full details of all Life Science Venture Capital deals from the past week plus profiles and analysis of thousands of investors and venture-backed companies.

October 28, 2012 – Fort Worth, TX

ZS Pharma Closes $46M Financing

ZS Pharma Inc., a Fort Worth, Texas-based specialty pharmaceutical company, has closed a $46m financing round.

The round was led by Alta Partners, with participation from new investors RiverVest Venture Partners, 3×5 Special Opportunity Partners and Salem Partners as well as current investor Devon Park Bioventures.

http://www.finsmes.com/2012/10/zs-pharma-closes-46m-financing.html

October 25, 2012 – Montreal, QC

Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Program

for Treatment of Acute Kidney Injury

Thrasos Therapeutics TM announced that it has completed a $35 Million (U.S.) financing for the development of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI). The round was led by new investor, SR One, with funds coming from the GSK Canada Life Sciences

Innovation Fund, part of GlaxoSmithKline’s commitment to advance the development and commercialization of scientific innovation in Canada. Five additional new investors and existing investor, SW Co, joined in the round. The new investors were Advanced Technology Ventures (ATV), Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures. With the financing, Thrasos plans to advance THR-184 through Phase 2 clinical proof of concept in AKI.

http://www.thrasos.com/about_us/Thrasos%20Series%20C%20Final%20English%20102512.pdf

October 24, 2012 – Austin, TX

Mirna Therapeutics Secures $34.5 Million Series C Financing to Advance Oncology microRNA Pipeline into the Clinic

Mirna Therapeutics Inc. (Mirna), a biopharmaceutical company focused on the development and commercialization of microRNA (miRNA) therapeutics in cancer, announced today the completion of a $34.5 million Series C financing. The company’s first institutional financing was led by Sofinnova Ventures, with participation from new investors, New Enterprise Associates (NEA), Pfizer Ventures, Osage University Partners, Correlation Ventures, and existing investors. The funding will enable Mirna to advance its lead microRNA-based therapeutic product candidate MRX34 through human proof of concept studies. As a result of the financing, Michael Powell Ph.D., General Partner, Sofinnova Ventures, Ed Mathers, Partner at NEA, and Elaine Jones, Ph.D., Executive Director, Venture Capital-Worldwide Business Development, Pfizer Inc., will join the Board of Directors.

http://www.vcaonline.com/news/news.asp?ID=2012102401#.UI5UxcUxqb5

October 24, 2012 – Malvern, PA

Aclaris Formed to Develop Novel Dermatology Treatment; Raises $21 Million in Series A Financing

Aclaris Therapeutics Inc., a privately held specialty pharmaceutical company dedicated to developing dermatological therapeutics, announced today that it has secured $21 million in Series A financing. The Series A was led by Vivo Ventures and Fidelity Biosciences with participation from Sofinnova Ventures. Proceeds from the financing will be used to fund the development of a novel topical dermatological product.

http://www.aclaristx.com/releases/release-1012.html

October 24, 2012 – Charlotteville, VA

HemoShear Closes $4M Fourth Equity Financing

HemoShear LLC, a Charlotteville, Va.-based biotechnology research company and developer of human and animal cell-based surrogate systems for discovery and assessment of new drug compounds, closed a $4m fourth equity financing.

The company intends to use the funding to move to larger lab and office facilities next year, invest in scientific and business staff, and provide working capital to accelerate growth.

http://www.finsmes.com/2012/10/hemoshear-closes-4m-fourth-equity-financing.html

October 25, 2012 – Santa Ana, CA

Health Essentials Receives Growth Capital Investment

Health Essentials, a Santa Ana, Calif.-based provider of post-acute care management services, has received a growth capital investment of undisclosed amount.

Backers include SV Life Sciences and Bessemer Venture Partners. The company intends to use the proceeds from the financing to continue to expand its services and geographies, while integrating and upgrading systems and infrastructure to further enhance the coordination of care for the most medically complex and at-risk patients.

http://www.finsmes.com/2012/10/health-essentials-receives-growth-capital-investment.html

Europe

October 22, 2012 – Rehovoth, Israel

Pharma Two B Completes $8M Second Financing Round

Pharma Two B Ltd., a Rehovoth, Israel-based company that focuses on developing Fixed-Dose-Combinations (FDCs) of two or more drugs with complementary and synergistic effects, has completed its $8m second round of financing. Backers include JK&B Capital, Michael Mittelman and Crossroad FCP-FIS.

http://www.finsmes.com/2012/10/pharma-completes-8m-financing.html

October 26, 2012 – Lyon, France

Biom’Up Raises €6.8M in Funding

Biom’Up, a Lyon, France-based manufacturer of re-absorbable medical devices, has raised €6.8m in funding. Backers include existing shareholders Merieux Developpement, SHAM, Sofimac Partners, Aquasourca and L’Ameliane, and new investors the InnoBio fund, managed by CDC Entreprises under the FSI France Investissement program, Viveris Management and OTC Asset Management.

http://www.finsmes.com/2012/10/biomup-raises-e6-8m-funding.html

October 23, 2012 – La Ciotat, France

Olea Medical Closes €4.2M Second Funding

Olea Medical, a La Ciotat, France-based provider of advanced medical imaging software, has closed a €4.2m second funding. The round was led by INNOVACOM, with the participation of oringinal investor EMAL. The company intends to use the capital to further accelerate its growth and international expansion.

http://www.finsmes.com/2012/10/olea-medical-closes-e4-2m-funding.html

This Week In Venture Capital is brought to you by VM Index – Venture Capital made easier

VM Index is an online IT, Life Science, Biotech & Med Tech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.

October 28, 2012 – Fort Worth, TX
ZS Pharma Closes $46M Financing
ZS Pharma Inc., a Fort Worth, Texas-based specialty pharmaceutical company, has closed a $46mfinancing round.
The round was led by Alta Partners, with participation from new investors RiverVest VenturePartners, 3×5 Special Opportunity Partners and Salem Partners as well as current investor DevonPark Bioventures.
http://www.finsmes.com/2012/10/zs-pharma-closes-46m-financing.html
October 25, 2012 – Montreal, QC
Thrasos Secures $35 Million to Fund THR-184 Phase 2 Clinical Programfor Treatment of Acute Kidney Injury
Thrasos Therapeutics TM announced that it has completed a $35 Million (U.S.) financing for thedevelopment of THR-184, its lead product candidate for the treatment of acute kidney injury (AKI).The round was led by new investor, SR One, with funds coming from the GSK Canada Life SciencesInnovation Fund, part of GlaxoSmithKline’s commitment to advance the development andcommercialization of scientific innovation in Canada. Five additional new investors and existinginvestor, SW Co, joined in the round. The new investors were Advanced Technology Ventures (ATV),Fonds de solidarité FTQ, Lumira Capital, MP Healthcare Venture Management and Pappas Ventures.With the financing, Thrasos plans to advance THR-184 through Phase 2 clinical proof of concept inAKI.
http://www.thrasos.com/about_us/Thrasos%20Series%20C%20Final%20English%20102512.pdf
October 24, 2012 – Austin, TX
Mirna Therapeutics Secures $34.5 Million Series C Financing to Advance Oncology microRNAPipeline into the Clinic
Mirna Therapeutics Inc. (Mirna), a biopharmaceutical company focused on the development andcommercialization of microRNA (miRNA) therapeutics in cancer, announced today the completionof a $34.5 million Series C financing. The company’s first institutional financing was led by SofinnovaVentures, with participation from new investors, New Enterprise Associates (NEA), Pfizer Ventures,Osage University Partners, Correlation Ventures, and existing investors. The funding will enable
Mirna to advance its lead microRNA-based therapeutic product candidate MRX34 through humanproof of concept studies. As a result of the financing, Michael Powell Ph.D., General Partner,Sofinnova Ventures, Ed Mathers, Partner at NEA, and Elaine Jones, Ph.D., Executive Director,Venture Capital-Worldwide Business Development, Pfizer Inc., will join the Board of Directors.
http://www.vcaonline.com/news/news.asp?ID=2012102401#.UI5UxcUxqb5
October 24, 2012 – Malvern, PA
Aclaris Formed to Develop Novel Dermatology Treatment; Raises $21 Million in Series A Financing
Aclaris Therapeutics Inc., a privately held specialty pharmaceutical company dedicated to developingdermatological therapeutics, announced today that it has secured $21 million in Series A financing.The Series A was led by Vivo Ventures and Fidelity Biosciences with participation from SofinnovaVentures. Proceeds from the financing will be used to fund the development of a novel topicaldermatological product.
http://www.aclaristx.com/releases/release-1012.html
October 24, 2012 – Charlotteville, VA
HemoShear Closes $4M Fourth Equity Financing
HemoShear LLC, a Charlotteville, Va.-based biotechnology research company and developerof human and animal cell-based surrogate systems for discovery and assessment of new drugcompounds, closed a $4m fourth equity financing.
The company intends to use the funding to move to larger lab and office facilities next year, invest inscientific and business staff, and provide working capital to accelerate growth.
http://www.finsmes.com/2012/10/hemoshear-closes-4m-fourth-equity-financing.html
October 25, 2012 – Santa Ana, CA
Health Essentials Receives Growth Capital Investment
Health Essentials, a Santa Ana, Calif.-based provider of post-acute care management services, hasreceived a growth capital investment of undisclosed amount.
Backers include SV Life Sciences and Bessemer Venture Partners. The company intends to use theproceeds from the financing to continue to expand its services and geographies, while integratingand upgrading systems and infrastructure to further enhance the coordination of care for the mostmedically complex and at-risk patients.
http://www.finsmes.com/2012/10/health-essentials-receives-growth-capital-investment.html
Europe
October 22, 2012 – Rehovoth, Israel
Pharma Two B Completes $8M Second Financing Round
Pharma Two B Ltd., a Rehovoth, Israel-based company that focuses on developing Fixed-Dose-Combinations (FDCs) of two or more drugs with complementary and synergistic effects, hascompleted its $8m second round of financing. Backers include JK&B Capital, Michael Mittelman andCrossroad FCP-FIS.
http://www.finsmes.com/2012/10/pharma-completes-8m-financing.html
October 26, 2012 – Lyon, France
Biom’Up Raises €6.8M in Funding
Biom’Up, a Lyon, France-based manufacturer of re-absorbable medical devices, has raised €6.8m infunding. Backers include existing shareholders Merieux Developpement, SHAM, Sofimac Partners,Aquasourca and L’Ameliane, and new investors the InnoBio fund, managed by CDC Entreprisesunder the FSI France Investissement program, Viveris Management and OTC Asset Management.
http://www.finsmes.com/2012/10/biomup-raises-e6-8m-funding.html
October 23, 2012 – La Ciotat, France
Olea Medical Closes €4.2M Second Funding
Olea Medical, a La Ciotat, France-based provider of advanced medical imaging software, has closeda €4.2m second funding. The round was led by INNOVACOM, with the participation of oringinalinvestor EMAL. The company intends to use the capital to further accelerate its growth andinternational expansion.
http://www.finsmes.com/2012/10/olea-medical-closes-e4-2m-funding.html

VM Index subscribers see full details of all Venture Capital deals from the past week plus profiles and analysis of thousands of investors and venture-backed companies.

North America

Europe

Breakdown By Sector

Life Sciences

Largest Deals

 TMT

Largest Deals

EXITS

This Week In Venture Capital is brought to you by VM Index – Venture Capital made easier 

VM Index is an online IT, Life Science, Biotech & Med Tech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.

VM Index subscribers see full details of all IT Venture Capital deals from the past week plus profiles and analysis of thousands of investors and venture-backed companies.

VM Index subscribers see full details of all Life Science Venture Capital deals from the past week plus profiles and analysis of thousands of investors and venture-backed companies.

October 19, 2012 – La Jolla, CA

Cebix Raises $30.9M in Series B Financing

Cebix, Inc., a La Jolla, California-based biopharmaceutical company developing treatments for complications of diabetes, has raised $30.9m in Series B financing. Backers include existing investors InterWest, Sofinnova Ventures and Thomas, McNerney & Partners.

http://www.finsmes.com/2012/10/cebix-raises-30-9m-series-financing.html

October 17, 2012 – New York, NY

Cibiem Raises $10M in Series A Financing

Cibiem, a New York City-based medical device startup, has raised $10m in Series A financing. Backers include SV Life Sciences and Third Rock Ventures.

Co-founded by CTO Mark Gelfand and President Howard R. Levin, M.D., Cibiem leverages its proprietary catheter-based approach focused on Carotid Body Modulation™ (CBM) for the treatment of sympathetic nervous system-mediated diseases such as hypertension, heart failure, diabetes and renal failure.

http://www.finsmes.com/2012/10/cibiem-raises-10m-series-financing.html

October 18, 2012 – Cambridge, MA 

Neurovance Closes $7M Series A1 Round for Development of EB-1020 for ADHD

Neurovance, Inc. today announced that it has closed a $7 million series A1 round led by existing investor Novartis Venture Fund to further advance development of EB-1020. Neurovance is a spinout of Euthymics Bioscience, Inc., its affiliated company under the same ownership. Neurovance was created to focus on development of EB-1020 for adult attention deficit hyperactivity disorder (ADHD) and a pipeline of research compounds for other CNS disorders.

http://finance.yahoo.com/news/neurovance-closes-7m-series-a1-113200571.html

October 15, 2012 – Boston, MA 

Healthrageous Secures $6.5 Million Series B Funding

Healthrageous, Inc., a leader in digital health self-management , has received $6.5 million in Series B financing from North Bridge Venture Partners, Egan-Managed Capital, Long River and an undisclosed investor. This latest round, which brings the company’s total financing to $15 million since 2010, will be used to further enhance its consumer facing user interfaces (web and mobile app), analytics engines, and machine learning platform. 

http://www.businesswire.com/news/home/20121015005280/en/Healthrageous-Secures-6.5-Million-Series-Funding

October 17, 2012 – Kalamazoo, MI

Tolera Therapeutics Closes $5.5M Series B-3 Financing 

Tolera Therapeutics Inc., a Kalamazoo, Michigan-based biotechnology company focusing on the development of immunotherapeutics directed at the transplantation, autoimmune and oncology markets, has closed its $5.5m Series B-3 financing. The round was led by Hopen Life Science Ventures, with participation from existing investors Triathlon Medical Venture Partners and SWMF Life Science Fund.

http://www.finsmes.com/2012/10/tolera-therapeutics-closes-5-5m-series-b-3-financing.html

October 15, 2012 – Malvern, PA

Promedior Adds $3M in Series D Financing

Promedior, Inc., a Malvern, PA-based clinical stage biotechnology company developing novel biologic therapeutics for the treatment of fibrosis, has adding $3m in a second closing of its $24.5m Series D financing.

The provider of the funding was new investor Shire Strategic Investment Group, which added to Fibrotec Ventures, Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group.

http://www.finsmes.com/2012/10/promedior-adds-3m-series-financing.html

Europe

October 19, 2012 – Stockholm, Sweden

Sprint Bioscience Raises Funding

Sprint Bioscience, a Stockholm, Sweden-based company developing oncology therapeutics targeting cancer metabolism, has raised a funding of undisclosed amount. Backers include Första Entreprenörsfonden and Almi Invest.

The company intends to use the capital to continue to build a pipeline of drug discovery projects within cancer metabolism.

http://www.finsmes.com/2012/10/sprint-bioscience-raises-funding-2.html

This Week In Venture Capital is brought to you by VM Index – Venture Capital made easier

VM Index is an online IT, Life Science, Biotech & Med Tech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.

VM Index subscribers see full details of all Venture Capital deals from the past week plus profiles and analysis of thousands of investors and venture-backed companies.

North America

Europe

Breakdown By Sector

Life Sciences

Largest Deals

 TMT

Largest Deals

EXITS

This Week In Venture Capital is brought to you by VM Index – Venture Capital made easier 

VM Index is an online IT, Life Science, Biotech & Med Tech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.

VM Index subscribers see full details of all IT Venture Capital deals from the past week plus profiles and analysis of thousands of investors and venture-backed companies.

VM Index subscribers see full details of all Life Science Venture Capital deals from the past week plus profiles and analysis of thousands of investors and venture-backed companies.

October 09, 2012 – Austin, TX

Calxeda Closes $55 Million Funding Round

Calxeda, the company that first invented the concept of using ARM® technology to slash data center power, today announced $55 million in additional funding, one of the largest semiconductor capital deals this year.  The funding is comprised of investments by Austin Ventures and Vulcan Capital plus additional participation by the firm’s existing investors.  Calxeda will use the funding to accelerate adoption and innovation in the emerging market for ultra-low power scalable computing.

http://www.calxeda.com/news-item/calxeda-closes-55-million-funding-round-new-investors-include-austin-ventures-vulcan-capital/

October 10, 2012 – Cambridge, MA

Genocea Biosciences Lands $30 Million Series C

Genocea Biosciences, Inc., a clinical-stage company advancing innovative T cell vaccines for infectious diseases, has raised $30 million in a Series C financing round. The Bill & Melinda Gates Foundation and CVF, LLC, an affiliate of Henry Crown and Company, are participating alongside all of Genocea’s existing investors, including Polaris Venture Partners, Lux Capital, SR One, Johnson & Johnson Development Corporation, Skyline Ventures, Cycad Group, Auriga Partners, MP Healthcare Ventures and Morningside. With the close of this financing round, Genocea has raised a total of $76 million in equity financing to date.

http://www.fiercebiotech.com/press-releases/genocea-biosciences-lands-30-million-series-c

October 09, 2012 – San Francisco, CA

LoneStar Heart Announces $20 Million Milestone Financing

LoneStar Heart Inc. today announced the completion of an up to $20 million  milestone-based equity financing  to support the clinical testing and regulatory clearance of its lead product,  Algisyl-LVR,  a single-use, self-gelling biopolymer implanted into the heart’s  left  ventricle  during  surgery  for the treatment of advanced heart failure.  Themes Investment Partners  (“Themes”),  a  Hong Kong-based private  equity fund focused on China markets, led the round. The new financing brings up to $35 million in equity funding since the company’s founding in June 2010.

http://www.lonestarheartinc.com/images/LSH_New_Financing_BIO_Forum_100512.pdf

October 08, 2012 – Baltimore, MD

Gliknik Raises $4.9 Million In Series B Financing Led By Baxter Ventures

Gliknik Inc., a privately held biopharmaceuticals company creating new therapies for cancer and immune / inflammatory disorders, today announced that it has raised $4.9 million in Series B Financing. Baxter Ventures, an initiative created in 2011 by Baxter International Inc., led the Series B raise and is joined by existing investors. With the funding, Gliknik will further advance towards the clinic its IVIG-mimetic lead compound, GL-2045, from its first-in-class stradomer™ platform.

http://www.prnewswire.com/news-releases/gliknik-raises-49-million-in-series-b-financing-led-by-baxter-ventures-173103351.html

October 11, 2012 – Washington, PA

RightCare Closes $1.75 Mln Series A Funding

RightCare Solutions, Inc., an evidence-based technology organization specializing in hospital discharge planning and readmission management, today announced it has secured Series A venture capital financing, led by Compass Partners, LLC and Domain Associates, LLC. The new funding will permit RightCare to further develop its unique Discharge Decision Support System Platform and expand early market adoption.

http://www.pehub.com/169161/rightcare-closes-1-75-mln-series-a-funding/

Europe

October 8, 2012 – Heidelberg, Germany

Affimed raises € 15.5 million in a Series D financing round

Affimed Therapeutics AG, the therapeutic TandAb antibody company, today announced the successful closing of a Series D financing round of € 15.5 million. The Series D financing round is lead by existing investors Aeris Capital, BioMedInvest, LSP Life Sciences Partners, Novo Nordisk A/S and Orbimed.

http://www.affimed.com/press-releases/19/2012-10-08-Affimed-raises-15-5-million-in-a-Series-D-financing-round

October 08, 2012 – Paris, France

EyeBrain Raises €3.3M in Second Funding

EyeBrain, a Paris, France-based startup developing brain function markers for neurological and psychiatric diseases, has raised €3.3m in second funding.

New backers Octalfa, Sudinnova and CM-CIC Capital Innovation have joined existing shareholders CapDecisif Management and G1JIDF, which invested 1.2m in the company’s first funding round in 2009.

http://www.finsmes.com/2012/10/eyebrain-raises-e3-3m-funding.html

Exits

October 8, 2012 – Burlington, MA

Boston Scientific to Acquire Rhythmia Medical

Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire privately-held Rhythmia Medical, Inc., a developer of next-generation mapping and navigation solutions for use in cardiac catheter ablations and other electrophysiology procedures, including atrial fibrillation and atrial flutter.  Rhythmia Medical is based in Burlington, MA.  The transaction is expected to close by Friday, October 12th.

http://www.prnewswire.com/news-releases/boston-scientific-to-acquire-rhythmia-medical-inc-173172731.html

October 10, 2012 – Irvine, CA

Edwards Lifesciences Acquires BMEYE

Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, announced today that it has completed the acquisition of BMEYE B.V., a privately held Dutch company that specializes in the development of non-invasive technology for advanced hemodynamic monitoring. BMEYE’s technology provides continuous, real-time information to clinicians and can be used in the surgical, intensive care, emergency room and cardiology settings.

http://www.edwards.com/newsroom/Pages/NR20121010.aspx

October 11, 2012 – New York, NY

Intercept Pharmaceuticals Announces IPO Pricing

Intercept Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock from Intercept. The Company’s shares are expected to begin trading on the NASDAQ on Thursday, October 11, 2012 under the trading symbol (ICPT).

http://www.forbes.com/sites/marketnewsvideo/2012/10/11/intercept-pharmaceuticals-announces-ipo-pricing/

This Week In Venture Capital is brought to you by VM Index – Venture Capital made easier

VM Index is an online IT, Life Science, Biotech & Med Tech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.

VM Index subscribers see full details of all Venture Capital deals from the past week plus profiles and analysis of thousands of investors and venture-backed companies.

North America

Europe

Breakdown By Sector

Life Sciences

Largest Deals

 TMT

Largest Deals

EXITS

This Week In Venture Capital is brought to you by VM Index – Venture Capital made easier 

VM Index is an online IT, Life Science, Biotech & Med Tech venture capital funding tool with expert data that enables companies to raise more money, faster and at a better valuation than they could otherwise.

VM Index subscribers see full details of all IT Venture Capital deals from the past week plus profiles and analysis of thousands of investors and venture-backed companies.